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Type 2 diabetes is triggered by reduced insulin
production, caused by genetic and environmental
factors such as inflammation originating from the
innate immune system. Complement proteins are a
component of innate immunity and kill non-self cells
by perforating the plasma membrane, a reaction
prevented by CD59. Human pancreatic islets ex-
press CD59 at very high levels. CD59 is primarily
known as a plasma membrane protein in membrane
rafts, but most CD59 protein in pancreatic b cells is
intracellular. Removing extracellular CD59 disrupts
membrane rafts and moderately stimulates insulin
secretion, whereas silencing intracellular CD59
markedly suppresses regulated secretion by exocy-
tosis, as demonstrated by TIRF imaging. CD59
interacts with the exocytotic proteins VAMP2 and
Syntaxin-1. CD59 expression is reduced by glucose
and in rodent diabetes models but upregulated in
human diabetic islets, potentially reflecting compen-
satory reactions. This unconventional action of CD59
broadens the established view of innate immunity in
type 2 diabetes.
INTRODUCTION
The innate immune system triggers tissue damage in autoim-
mune diseases (Diana et al., 2011), but it may also be a central
player in other types of human disease. For example, type 2
diabetes has been coined an autoinflammatory disease, in
which dysregulated immunity causes disturbances in insulin
production in pancreatic b cells and signaling in target tissues
(Donath and Shoelson, 2011; Odegaard and Chawla, 2013).
Innate immunity includes the complement system, with more
than 30 proteins present in large quantities in the circulation
and also locally in tissues. Complement represents a first
line of defense against invading pathogens and also aids
removal of apoptotic and transformed cells (Ricklin et al.,C2010). Complement proteins are primarily produced in the
liver, but there is extensive evidence for local expression in
peripheral tissues (Andoh et al., 1998; Passwell et al., 1990;
Strainic et al., 2008).
Complement protein expression in pancreatic b cells and their
interplay with insulin production and the secretion machinery
remain largely unexplored. However, there are reports of high
expression of the membrane-associated complement inhibitor
CD59 in human pancreatic islets (Bennet et al., 2001). In addi-
tion, soluble glycated CD59 may be a potential biomarker for
type 2 diabetes (Ghosh et al., 2013). CD59 is a glycosylphospha-
tidylinositol (GPI)-linked protein located in lipid rafts (Miwa et al.,
2012), which are membrane domains highly enriched with
cholesterol and sphingomyelins (Suzuki et al., 2012). Lipid rafts
act as platforms which enhance cellular signaling (Reeves
et al., 2012), and are also suggested to cluster exocytotic pro-
teins and influence secretion of hormones (Lang, 2007). Here,
we investigated the expression of complement genes in pancre-
atic islets, and detailed the impact of CD59 on insulin secretion.
Our data demonstrate an unanticipated function of CD59 other
than its classical role in complement-mediated cell lysis. This un-
conventional CD59 action is directed at themolecular machinery
of b cell exocytosis and appears to be engaged during the devel-
opment of type 2 diabetes.RESULTS AND DISCUSSION
CD59 Is theMost Highly ExpressedComplementGene in
Pancreatic Islets, with Decreased Islet Expression in
Rodent Diabetes Models
First, we determined the expression of complement genes by
microarray in human pancreatic islets from 112 donors. Of 32
investigated genes, 21 were significantly expressed over back-
ground, which was defined as the average of all negative con-
trol probes. The gene showing the highest signal was the com-
plement inhibitor CD59 (Figure 1A). The spontaneously diabetic
Goto-Kakizaki (GK) rat shares many hallmarks of human type 2
diabetes and develops several of the late complications. Insulin
secretion in GK rats is reduced from an early age and deterio-
rates as diabetes develops (Ostenson et al., 1993). Out of the
nine significantly expressed genes in GK and healthy Wistarell Metabolism 19, 883–890, May 6, 2014 ª2014 Elsevier Inc. 883
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Figure 1. Expression of Complement Genes
(A) Complement genes significantly expressed over background in expression microarrays of human pancreatic islets (n = 112).
(B) Expression of complement genes in Wistar and GK rat islets; n = 3, **p < 0.01.
(C) Expression of CD59 in diabetes-resistant (DR) and diabetes-prone (DP) BB rat islets; n = 4 for each group; *p < 0.05.
(D) CD59 expression in islets from diabetic Akita and control nondiabetic WT mice; n = 5 for Akita and 7 for WT; *p < 0.05.
(E) Expression of CD59 in INS-1 832/13 cells after culture in 2.8 or 16.7 mM glucose for 2–72 hr; n = 3, **p < 0.01 and ***p < 0.001.
(F) Expression of CD59 in human islets cultured for 24 hr in 5.5 or 18.9 mM glucose measured with RNA sequencing; n = 53, **p < 0.01.
(G). Localization of CD59 in a pancreatic rat islet; n = 3.
(H) Colocalization of CD59 (red) and insulin (green) in permeabilized primary rat islet cells; n = 3.
(I) Percent of colocalization after culture at 2.8 or 16.7 mM glucose for 1 hr. The bars on the left indicate the amount of CD59 colocalized with insulin, and the bars
on the right show the amount of insulin colocalized with CD59. *p < 0.05. See also Figure S1E. All values aremeans ± SEM.mRNA levels are related to HPRT in (B),
(D), and (E) and to HPRT and Pol2a in (C).
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compared to Wistar islets (Figure 1B). Average CD59 protein
levels in islets and erythrocytes tended to decrease in GK884 Cell Metabolism 19, 883–890, May 6, 2014 ª2014 Elsevier Inc.(see Figures S1C and S1D online). The decreased gene expres-
sion of CD59 in GK islets was also confirmed in two other ro-
dent models of diabetes: the Akita mouse (Wang et al., 1999)
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Figure 2. Silencing of CD59 in INS-1 832/13 Cells Decreases Insulin
Secretion and Exocytosis
(A) Expression of CD59 in unpermeabilized and permeabilized INS-1 832/13
cells; n = 3. CD59 is located in the plasma membrane as well as in the cytosol.
(B) CD59 mRNA levels relative to HPRT in siRNA control cells and cells treated
with siRNA against CD59, 48 hr after transfection. Values are means ± SEM for
three independent experiments; **p < 0.01. See also Figure S2A.
(C) CD59 protein expression levels 72 hr after silencing of CD59 analyzed by
flow cytometry. Expression levels are shown as mean fluorescent intensity
(percentage of untreated cells). Values are means ± SEM for four independent
experiments. **p < 0.01. See also Figure S2B.
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Cand the BB rat (Akesson et al., 2007) (Figures 1C and 1D). To
explore whether the decreased expression could be driven by
high blood glucose, CD59 expression was investigated after
high-glucose incubations. In clonal rat b cells (Figure 1E) as
well as human islets (Figure 1F), exposure to high glucose
decreased CD59 expression. Immunostaining of rat pancreas
revealed that CD59 was expressed both in the islets and in
the surrounding exocrine tissue (Figure 1G). In addition to the
expected plasma membrane location, CD59 was also found
to colocalize with insulin in b cells. The degree of colocalization
increased when islets were incubated in high concentrations of
glucose (Figures 1H, 1I, and S1E). The insulin colocalization is
intriguing, since CD59 has previously only been regarded as
a membrane protein found on the extracellular surface (Kim
and Song, 2006; Kimberley et al., 2007; Suzuki et al., 2012).
The intracellular expression and colocalization with insulin
granules suggested to us that CD59 may have additional func-
tions in the b cell.
Silencing of CD59 Decreases Insulin Secretion by
Reducing the Number of Exocytotic Events
The localization of CD59 to insulin granulesmade us hypothesize
that reduced CD59 expression could impair insulin secretion.
Consequently, we silenced CD59 by RNA interference in insu-
lin-secreting rat INS-1 832/13 cells (Hohmeier et al., 2000). First,
CD59 expression was verified in these cells, both on the plasma
membrane and intracellularly (Figure 2A). Silencing was verified
by both Q-PCR (Figure 2B) and flow cytometry (Figures 2C
and S2B) and had no effect on total insulin content (Figure 2D).
We then investigated the functional consequences of CD59
silencing. Insulin secretion was stimulated with three secreta-
gogues acting at various stages of the stimulus-secretion
coupling in b cells (16.7 mM glucose, 10 mM a-KIC, and
35 mM K+) in order to pinpoint the functional stage of action.
Glucose undergoes glycolysis prior to mitochondrial meta-
bolism, a-KIC acts as a mitochondrial substrate, and depola-
rizing concentrations of K+ bypass metabolism and directly
activate the voltage-gated Ca2+ channels to trigger exocytosis.
In the CD59-silenced cells, basal secretion was unaffected,
whereas insulin secretion was strongly and equally reduced in(D) Insulin content in silenced cells does not differ from control cells. Values are
means ± SEM for three independent experiments.
(E) Insulin secretion in static incubations is decreased after silencing of CD59.
After siRNA transfection (72 hr), 832/13 clonal b cells were stimulated with
2.8 mM glucose (glc), 16.7 mM glucose, or 2.8 mM glucose combined with
10mM a-KIC or 35mMK+, respectively, over 1 hr. Values aremeans ± SEM for
three independent experiments. For glucose and a-KIC, ***p < 0.001. For K+,
**p < 0.01. See also Figure S2C.
(F and G) Examples of single-granule exocytosis events measured with TIRF
microscopy for siCtrl (F) and siCD59 (G); frames are 100 ms apart.
(H) Traces of granule fluorescence for the events in (F) and (G); squares,
siCD59; circles, siCtrl.
(I) Averages of all traces as in (H) aligned to the first frame different from
baseline (indicated by asterisks in F and G).
(J–L) (J) Decay time and (K and L) cumulative number of events per area
detected in siCtrl and siCD59 cells and event frequency as defined in the text.
The data are derived from 63 events detected in six independent experi-
ments (cells) for siCtrl and 22 events in 11 cells for siCD59. Values are means ±
SEM. See also Figures S2E–S2G.
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Figure 3. Extracellular CD59 in Lipid Rafts and Insulin Secretion
(A) Staining of lipid rafts in Wistar and GK rat islet cells reveals a significant
lower mean intensity of lipid raft staining in the GK rat; n = 3, *p < 0.05.
(B) Silencing of CD59 in INS-1 832/13 cells decreases the amount of lipid rafts;
n = 4, *p < 0.05.
(C) Silencing of CD59 in epithelial A549 cells exhibits the same decrease of lipid
rafts as in b cells, and proves the effect to be general and not specific for islet
cells; n = 4, *p < 0.05. Values are means and SEM for three to four independent
experiments for all lipid raft stainings.
(D) Treatment with PLC strips the plasma membrane of GPI-linked proteins,
including CD59. Analyses with flow cytometry showed that 1 U/ml of PLC
removes all extracellular CD59 from INS-1 832/13 cells; n = 3. Horizontal line,
background fluorescence (isotype ctrl).
(E) Insulin secretion in INS-1 832/13 cells treated with PLC (1 U/ml). The effect
on insulin secretion when extracellular CD59 is removed does not mimic the
effect of CD59 silencing; n = 5, *p < 0.05.
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886 Cell Metabolism 19, 883–890, May 6, 2014 ª2014 Elsevier Inc.response to all three secretagogues (60%, 66%, and 63%,
respectively; Figure 2E). The effect of silencing CD59 on
glucose-stimulated insulin secretion was confirmed using two
other siRNAs (Figure S2C) and also in glucagon-secreting
aTC1-6 cells (Figure S2D).
The similar decrease in secretion in response to all tested se-
cretagogues suggests that the site of inhibition is distal to meta-
bolismand ismost likely directly affecting theexocytotic reaction.
We therefore investigated this process using total internal reflec-
tion (TIRF) microscopy. To address whether silencing of CD59
affects the release kinetics from individual granules, INS-1 832/
13 cells were cotransfected with the granule marker NPY-EGFP
and siRNA against CD59 or control siRNA, and exocytosis was
stimulated by exposure to high K+. Individual exocytotic events
were seen as rapid disappearance of individual granules, as
shown in Figure 2F (control) and 2G (CD59 siRNA). Interestingly,
24% of the events in control cells were preceded by a bright
flash indicating fusion pore formation (Barg et al., 2002), which
occurredmore rarely (14%) after CD59 silencing. The latter effect
was probably due to faster release kinetics, which we analyzed
by extracting the fluorescence time course of individual events
(examples in Figure 2H). We aligned the traces to the first signifi-
cant change from baseline, taken as the moment of fusion pore
opening. The aligned average of CD59 silenced cells decayed
to zero faster than controls, indicating faster granule emptying
upon exocytosis (Figures 2I and 2J).
However, the most striking finding was the dramatic reduction
in the number of detected exocytotic events in response to K+
in CD59 silenced cells (two events per cell versus 11 in control
cells). Normalized for the area of the cell’s footprint, this trans-
lates to 0.13 ± 0.02 min1mm2 in controls (six cells with 63
events) compared to 0.01 ± 0.01 min1mm2 in CD59-silenced
cells (11 cells with 22 events) (Figures 2K and 2L). The same
reduction was seen also when only analyzing events with
preceding flashes (Figure S2G). In summary, silencing of
CD59 strongly reduced the number of exocytosis events but
accelerated the release kinetics of the individual events that
did occur.
CD59 Is Important for Lipid Raft Stability
The location of CD59 in lipid rafts and its use as a lipid raft marker
suggest that it might be of importance for these structures. We
therefore stained lipid rafts using the lipid raft component sphin-
gomyelin, fluorescently labeled with Atto647N (Eggeling et al.,
2009). Staining of islet cells from healthy Wistar rats and diabetic
GK exhibited a clear difference in lipid raft appearance. The lipid
raft structure in GK rat islets was disrupted, and the overall stain-
ing intensity was significantly lower (Figure 3A). A similar reduc-
tion in lipid raft staining was observed in INS-1 832/13 cells
silenced for CD59 (Figure 3B), as well as in CD59-silenced
epithelial A549 cells (Figure 3C). Collectively, these observations
strongly support that CD59 plays an important role in stabilizing
lipid rafts, which is not restricted to endocrine cells.(F) INS-1 832/13 cells stably overexpressing the GPI-linked protein Thy-1 were
silenced for CD59 72 hr prior to insulin secretion. Thy-1 overexpression did not
rescue the decreased insulin secretion caused by CD59 silencing; n = 4, **p <
0.01. Values are means and SEM for three to five independent experiments.
See also Figure S3.
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Insulin Secretion
Phospholipase C strips the plasmamembrane of GPI-linked pro-
teins including CD59, leaving only the diacylglycerol anchor in
the plasma membrane. As a complementary method for CD59
removal, we treated INS-1 832/13 cells with PLC and verified
the loss of cell surface CD59 by flow cytometry. With 1 U/ml
PLC the extracellular CD59 signal was reduced to background
levels (Figure 3D). PLC-treated cells and controls were then stim-
ulated with glucose. Remarkably, the effect on insulin secretion
after PLC treatment bore little resemblance to the effect of
CD59 silencing by siRNA. First, basal insulin release at 2.8 mM
glucose was significantly increased. Second, insulin secretion
evoked by high glucose (16.7 mM) was unaffected by PLC treat-
ment as compared to control cells (Figure 3E). To further inves-
tigate the specificity of the influence of CD59 on insulin secretion,
we stably overexpressed an alternative GPI-linked protein,
Thy-1, in INS-1 832/13 cells (Figure S3A). These cells were
then silenced for CD59 and assayed for insulin secretion (Figures
3F and S3B). Thy-1 overexpression did not rescue impaired insu-
lin secretion fromCD59-silenced cells. Collectively, these results
suggest the involvement of two distinct mechanisms whereby
CD59 controls insulin secretion: the plasma membrane pool of
CD59 is responsible for stabilization of lipid rafts, and disruption
of lipid rafts results in increased basal secretion. By contrast, the
intracellular pool of CD59 that is colocalized with insulin, and
is removed by siRNA knockdown, but not by extracellular PLC,
is important for stimulated insulin secretion and regulated
exocytosis.
CD59 Is Responsible for Establishing the VAMP2-
Syntaxin Complex
Wehypothesized that intracellular CD59 regulates exocytosis via
interactionwith the exocytotic machinery. SNARE proteins (solu-
ble N-ethylmaleimide-sensitive factor attachment protein recep-
tor) control insulin granule fusionwith the plasmamembrane. The
transmembrane protein syntaxin1A and the membrane-associ-
ated protein SNAP-25 are predominantly associated with the
plasma membrane, whereas VAMP2 is a vesicular membrane
protein (Gerber and Su¨dhof, 2002). Upon Ca2+ entry, the SNARE
complex changes conformation forcing the granule to fuse with
the plasma membrane (Jahn et al., 2003). Immunostainings sug-
gested that CD59 colocalized with syntaxin1A and VAMP2 (Fig-
ures 4Aand4B). To investigate the interactionswith better spatial
stringency, we used the Duolink in situ detection method. Paired
species-specific secondary antibodies with unique DNA oligo-
nucleotides (proximity ligation assay [PLA] probes) were used.
When the PLA probes are in close proximity (<40 nm), the DNA
strands interact and the signal is amplified via rolling circle ampli-
fication using a polymerase, yielding distinct bright dots of fluo-
rescence. Cells were incubated in 2.8 and 16.7 mM glucose
and then stained with either CD59 + syntaxin1A or CD59 +
VAMP2 antibodies linked with Duolink. CD59 interacted with
both syntaxin1A and VAMP2, as demonstrated by the appear-
ance of distinct dots (Figure 4C). These interactions between
CD59 and the exocytotic proteins increased significantly upon
stimulation with glucose (Figure 4D). Next, we investigated
whether CD59 plays a role in establishing the exocytotic fusion
complex. Hence, Duolinkwith syntaxin1A andVAMP2antibodiesCwasperformed in cells silenced forCD59. In control cells, interac-
tionsbetweensyntaxin andVAMP2 increased significantly in high
glucose, as expected under conditions stimulating exocytosis.
However, in the CD59-silenced cells, glucose stimulation failed
to do so (Figures 4E and S4A). Instead, these remained static at
an intermediate level. Similar results were obtained when using
high K+ as stimulus (Figure S4C). As control, no increased inter-
action between CD59 and the lipid raft marker flotillin was
observed in 16.7 mM glucose (Figure S4B). With ELISA, a similar
increase in interactions betweenCD59andVAMP2or syntaxin1A
was seen upon glucose stimulation (Figure 4F). Further evidence
of interactionswas obtained by immunoprecipitation, where syn-
taxin1A bound both CD59 and VAMP2 (Figure 4G). Interestingly,
only one formofCD59wasdetected in theeluate, suggesting that
the effect may involve only a subpopulation of CD59. Thus, CD59
influences the SNARE pairing required for exocytosis. The inter-
mediate state reached in the silenced cells indicates that the role
of CD59 could be to assist in the break-up or recycling of the
exocytotic core complex postfusion, and that in the absence of
CD59, inactive complexes accumulate and hence new ones
cannot be formed. A role for CD59 in dissociation of the exocy-
totic complex could also provide ideas for further studies on the
increased kinetics of the individual exocytotic events that do
occur in CD59-silenced cells (Figure 2I).
Concerning the role of CD59 during diabetes development,
reduced islet expression was observed in three different rodent
models under conditions not associated with changes in b cell
mass, as well as after 24 hr high-glucose treatment in rat clonal
cells and human islets. However, human islet CD59 expression
exhibited a paradoxical positive correlation to clinical glucose
control of the donors (HbA1c levels; Figures S1A and S1B). A
possible explanation to this is that this finding reflects the
attempt of b cells at compensating for a deteriorating insulin
output. In fact, a major lesson from global RNA sequencing en-
deavors is that expression in diabetic islets can be very different
from those observed in the prediabetic state when themajority of
gene expression changes are observed (J. Fadista, I. Mollet, and
L. Groop, personal communication). A broader knowledge of
islet gene expression changes during diabetes will help to put
the present findings into perspective.
In summary, this study demonstrates a previously unknown
interaction between a component of the innate immune system
and the molecular machinery of hormone secretion. We demon-
strate that the complement inhibitor CD59 exerts unconventional
effects other than its well-known suppression of the lytic
membrane attack complex. First, CD59 appears to play a role in
maintaining lipid raft stability in different cell types,which in b cells
has consequences for basal insulin release rates. Second, CD59
facilitates recycling of exocytotic core proteins, and in its absence
this process is arrested. This work paves the way for further
studies on the roles of CD59 and the complement system in lipid
raft biology and in hormonal disorders such as type 2 diabetes.EXPERIMENTAL PROCEDURES
Human Islets
Human islets were provided by the Nordic Network for Islet Transplantation,
Uppsala University. All procedures were approved by the ethics committees
at Uppsala and Lund Universities.ell Metabolism 19, 883–890, May 6, 2014 ª2014 Elsevier Inc. 887
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Figure 4. CD59 Is Necessary for VAMP2 and Syntaxin 1A Colocalization
(A) CD59 colocalizes with VAMP2; n = 3.
(B) CD59 colocalizes with Syntaxin 1A; n = 3.
(C) Colocalization of CD59with VAMP 2 and Syntaxin 1A using Olink PLA probes. A flouorescent dot is generatedwhen two antibodies are closer than 40 nM. See
also Figure S4A.
(D) Quantification of Olink colocalization. Colocalization of CD59 and VAMP2 as well as CD59 and Syntaxin 1A increases in high concentrations of glucose.
(legend continued on next page)
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Wistar, GK, and BB rats and Akita mice of age 5–13 weeks were used in this
study. All procedures were approved by the local ethics review board at
Lund University and the Malmo¨/Lund Animal Care and Use Committee.
Gene Expression Analysis
Microarray in Human Pancreatic Islets
RNA isolation from human islets was performed using the AllPrep DNA/RNA
Mini Kit (QIAGEN). Concentration and purity was measured using a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies). Themicroarrays were
performed following the Affymetrix standard protocol for Human Gene 1.0 ST
whole-transcript-based assay. Data were summarized and normalized with
the RMA analysis method using R.
Quantitative PCR
RNA was extracted using RNEasy (QIAGEN). Gene expression was measured
by QPCR using TaqMan (AppliedBiosystems).
RNA Sequencing
Total RNA was extracted from 55 islet donors, and RNA-seq libraries were
generated (TruSeq RNA sample preparation kit, Illumina) and sequenced on
an Illumina HiSeq 2000 using paired-end chemistry and 100 bp cycles to an
average depth of 32 M read pairs per sample. Reads were aligned to hg19
using STAR (Dobin et al., 2013) and read count calculated by HTSeq-count
(Anders et al., 2014) and normalized using trimmed mean of M values.
Immunostainings
CD59, insulin, and glucagon were visualized by indirect immunohisto-/cyto-
chemistry in pancreatic sections from normal rats, dispersed to INS-1 832/
13 or primary rat islet cells by indirect immunocytochemistry.
siRNA Transfection
siRNA transfection was performed using Dharmafect (Dharmacon) and 30 nM
oligonucleotides.
Flow Cytometry
Cellular CD59 levels were assessed using mouse anti-rat CD59 (AbD serotec),
followed by a FITC-labeled anti-mouse secondary (DAKO). For intracellular
staining, cells were fixed using Fix&Perm kit (ADG Bioresearch) and then per-
meabilized using 0.5% Tween 20. Insulin costaining was performed using
1:200 guinea pig anti-insulin serum (Euro Proxima) followed by 1:200 anti-
guinea pig Cy5. Cells were analyzed using the Cyflow Space flow cytometer
(Partec).
Insulin Secretion
INS1-832/13 cells were preincubated for 2 hr in 2.8mMglucose and then stim-
ulated with 2.8 or 16.7 mM glucose or 2.8 mM glucose combined with 10 mM
a-KIC or 35 mM K+ for 1 hr.
TIRF Microscopy
INS-1 832/13 cells were imaged using a custom-built TIRF microscope.
Exocytotic events were analyzed as detailed in the Supplemental Information.
Duolink In Situ Detection
INS-1 832/13 cells were incubated with primary antibodies of antibodies of
anti-CD59 (NordicBioSite, AbD serotec), anti-VAMP2 (Abcam), and anti-syn-
taxin 1A (SYSY) overnight. Continuous staining protocol followed the instruc-
tion from Olink Bioscience.
ELISA
INS-1 832/13 cells were lysed after incubation for 24 hr in 2.8 or 16.7 mM
glucose. Lysates were incubated for 1 hr in microtiter plates coated
with anti-VAMP2 (SYSY), anti-syntaxin 1 (SYSY), or isotype control antibodies(E) Quantification of Olink colocalization of VAMP2 and Syntaxin 1A in cells where
glucose concentrations, whereas in the silenced cells there is no response to high
0.001. See also Figure S4B.
(F) Binding of CD59 to VAMP2 and Syntaxin 1A in INS-1 832/13 cells measured
(G) Immunoprecipitation with Syntaxin 1A antibodies in INS-1 832/13 cells. Both
C(Immunotools). CD59 was then detected with biotinylated mouse antibodies
followed by streptavidin-HRP (R&D). Absorbance was measured at 490 nm.
Immunoprecipitation
INS-1 832/13 cells were incubated in 16.7 mM glucose for 24 hr. After lysis, an
aliquot was saved as ‘‘Input’’ sample. Remaining lysate was mixed with anti-
syntaxin-1 (SYSY) or isotype control covalently bound tomagnetic DynaBeads
(Invitrogen, Life Technologies, USA) and incubated overnight. Beads were
extensively washed with lysis buffer and coprecipitated proteins eluted.
Statistics
Group means were compared with Student’s unpaired two tailed t test when
two groups were compared, and with one-way ANOVA when multiple groups
were compared. The Bonferroni method was used in case of multiple compar-
isons. The level of significance was set at p < 0.05.
Detailed protocols are appended in the Supplemental Information.
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